Related Experiment Video
Updated: Jan 5, 2026

Author Spotlight: Dendritic Cells Maturation Using Sialidases-Based Enzymatic Treatment of the Cell Surface
Published on: October 20, 2023
Targeting Aberrant Sialylation to Treat Cancer
Jennifer Munkley1, Emma Scott2
1Institute of Genetic Medicine, Newcastle University, Newcastle upon Tyne NE1 3BZ, UK. Jennifer.munkley@ncl.ac.uk.
Abstract:
Cell surface carbohydrates (known as glycans) are often aberrantly expressed or found at atypical levels in cancer. Glycans can impact all steps in tumour progression, from malignant transformation to metastasis, and have roles in all the cancer hallmarks. An increased understanding of glycans in the metastatic cascade offers exciting new therapeutic opportunities. Glycan-based targeting strategies are currently being tested in clinical trials and are a rich and untapped frontier for development. As we learn more about cancer glycobiology, new targets will continue to emerge for drug design. One key change in tumour glycosylation is the upregulation of cancer-associated sialylated glycans. Abnormal sialylation is integral to tumour growth, metastasis and immune evasion; therefore, targeting sialic acid moieties in cancer could be of high therapeutic value. Here, we summarise the changes to sialic acid biology in cancer and discuss recent advances and technologies bringing sialic-acid targeting treatments to the forefront of cancer therapeutics.
Insights
Cancer cell surface glycans, particularly sialylated glycans, drive tumor progression and metastasis. Targeting these aberrant sialic acid structures offers promising new therapeutic strategies for cancer treatment.
Area of Science:
- Biochemistry
- Oncology
- Glycobiology
Background:
- Cell surface carbohydrates (glycans) are frequently altered in cancer, influencing tumor progression and metastasis.
- Aberrant glycan expression is implicated in all hallmarks of cancer.
- Understanding cancer glycobiology, especially sialic acid modifications, presents therapeutic opportunities.
Purpose of the Study:
- To summarize alterations in sialic acid biology within cancer.
- To discuss advancements in targeting sialic acid for cancer therapeutics.
Main Methods:
- Review of current literature on cancer glycobiology and sialic acid.
- Analysis of emerging technologies for sialic acid-targeted therapies.
Main Results:
- Upregulation of cancer-associated sialylated glycans is a key change in tumors.
- Abnormal sialylation contributes to tumor growth, metastasis, and immune evasion.
- Glycan-based targeting strategies are under clinical investigation.
Conclusions:
- Targeting sialic acid moieties holds significant therapeutic potential in oncology.
- Advances in understanding and targeting cancer glycans are paving the way for novel treatments.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Abnormal Proliferation

